FDA Approvals of Binimetinib in Combination with Encorafenib: Advancements in Targeted Therapy for Metastatic Melanoma and Non-Small Cell Lung Cancer with BRAF V600E Mutation

In a significant stride towards combating metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, the FDA has granted approval for the use of binimetinib in combination with encorafenib. This approval comes on the heels of the promising results from the PHAROS study, which showcased the efficacy of binimetinib and encorafenib in terms of objective response rate (ORR) and duration of response (DoR). Additionally, companion diagnostics for detecting the BRAF V600E mutation have also received FDA approval, ensuring accurate patient selection for this treatment.

Approval and Efficacy

The FDA's approval of binimetinib demonstrates its efficacy in combination with encorafenib for the treatment of unresectable or metastatic melanoma with a BRAF V600E or V600K mutation. This approval was based on data from a randomized, active-controlled, open-label, multicenter trial called COLUMBUS (NCT01909453), which included 577 patients. The trial compared the efficacy of binimetinib plus encorafenib, encorafenib alone, and vemurafenib.

The primary measure of efficacy was progression-free survival (PFS) using RECIST 1.1 response criteria. The median PFS for patients receiving binimetinib plus encorafenib was 14.9 months. These results demonstrate the significant clinical benefit of this combination therapy for patients with unresectable or metastatic melanoma.

In terms of safety, the most common adverse reactions reported in patients receiving the combination were lack of energy, nausea, diarrhea, vomiting, abdominal pain, and arthralgia. In general, 5% of individuals discontinued therapy due to adverse reactions, with hemorrhage and headache being the most common reasons for discontinuation.

It is important to note that these clinical trial results provide valuable insights into the efficacy and safety profile of binimetinib plus encorafenib. However, real-world effectiveness and long-term outcomes may differ from those observed in clinical trials. Healthcare professionals should closely monitor patients receiving this treatment and report any serious adverse events suspected to be associated with the use of these drugs.

Adverse Reactions

Common adverse reactions were observed in patients receiving the combination of binimetinib plus encorafenib for the treatment of unresectable or metastatic melanoma. These adverse reactions included fatigue, nausea, diarrhea, vomiting, abdominal pain, and arthralgia. In clinical trials, 5% of patients receiving the combination therapy discontinued treatment due to these adverse reactions. The most common reasons for discontinuation were hemorrhage and headache.

It is important for healthcare professionals to document all serious adverse events related to binimetinib plus encorafenib. Adverse events reporting is crucial for monitoring the safety profile of these drugs and ensuring patient safety.

In addition to the common adverse reactions, there have been serious adverse reactions in patients receiving both binimetinib and encorafenib. These events may require immediate medical attention and intervention.

Companion Diagnostic

The approval of binimetinib by the FDA also included the recognition of the THxID BRAF Kit as a companion diagnostic for the analysis of BRAF V600E or V600K mutation in patients with melanoma. A companion diagnostic is a test or device used to determine which patients are most likely to respond well to a specific treatment. In the case of binimetinib, the THxID BRAF Kit is used to determine if a patient's melanoma has the specific BRAF mutation that makes them eligible for treatment with binimetinib.

Companion diagnostics play a crucial role in patient selection, as they ensure that the right patients receive the appropriate treatment. By accurately identifying patients with the BRAF V600E or V600K mutation, the THxID BRAF Kit helps healthcare professionals make informed treatment decisions.

The use of companion diagnostics is supported by real-world data and cost-effectiveness analyses, which demonstrate the long-term safety and treatment response of binimetinib in patients with the specific BRAF mutation. By incorporating the THxID BRAF Kit into the treatment process, healthcare professionals can optimize patient outcomes by tailoring therapy to those who are most likely to benefit.

Prescribing Information

Prescribing information for binimetinib provides healthcare professionals with detailed dosing and administration instructions, as well as important information on clinical trial data, efficacy, safety, drug interactions, warnings, and precautions. These guidelines ensure that healthcare providers can effectively and safely prescribe binimetinib to their patients.

The prescribing information includes specific dosing guidelines, outlining the suggested dosage and frequency of administration for binimetinib. This helps healthcare professionals ensure that patients receive the appropriate amount of the medication for their condition.

Additionally, the prescribing information contains valuable clinical trial data, which provides evidence of the drug's effectiveness in treating the targeted condition. This data includes information on the study design, patient population, and results, helping healthcare professionals make informed decisions about the use of binimetinib.

Safety precautions and warnings are also included in the prescribing information. These precautions highlight potential adverse reactions, drug interactions, and other safety considerations that healthcare professionals should be aware of when prescribing binimetinib.

Furthermore, the prescribing information emphasizes the importance of healthcare reporting. Healthcare professionals are encouraged to report any serious adverse events or suspected adverse reactions associated with binimetinib to the appropriate regulatory authorities. This reporting helps to ensure the ongoing safety monitoring of the medication.

Reporting and Additional Resources

Healthcare professionals should prioritize the reporting of adverse reactions suspected to be associated with the use of binimetinib to ensure ongoing safety monitoring. It is important to report these events to the FDA's MedWatch Reporting System or by calling 1-800-FDA-1088. This reporting is crucial for the continuous evaluation of the drug's safety profile and to identify any potential risks or concerns.

In addition to reporting adverse events, healthcare professionals receive updates and resources related to binimetinib and other approved drugs through various channels. The FDA Oncology Twitter account, @FDAOncology, provides updates on recent approvals, regulatory actions, and other important information in the field of oncology. The Oncology Center of Excellence (OCE) also offers a podcast called the Drug Information Soundcast in Clinical Oncology, which provides valuable insights and updates on recent approvals.

Furthermore, healthcare professionals can access resources for information on approved drugs and therapeutic equivalence evaluations. These resources provide detailed information on the clinical trial data, efficacy, safety, drug interactions, warnings, precautions, and recommended doses for binimetinib and other approved drugs. By utilizing these additional resources, healthcare professionals can ensure they have the most up-to-date information to guide their clinical practice and decision-making.

Conclusion

In conclusion, the FDA approval of binimetinib and its companion diagnostic tests represents a significant milestone for treating NSCLC with a BRAF V600E mutation. The findings of the PHAROS study provided evidence of the efficacy of binimetinib and encorafenib in this patient population. With accurate patient selection using the approved diagnostic tests, healthcare professionals can now confidently prescribe this targeted treatment, bringing hope to patients with this specific mutation.

Bibliography

Center. "FDA Approves Encorafenib and Binimetinib in Combination For ..." U.S. Food and Drug Administration, 2018, (https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-encorafenib-and-binimetinib-combination-unresectable-or-metastatic-melanoma-braf)
‌Shirley M. Encorafenib and Binimetinib: First Global Approvals. Drugs. 2018 Aug;78(12):1277-1284. doi: 10.1007/s40265-018-0963-x. PMID: 30117021. (https://pubmed.ncbi.nlm.nih.gov/30117021/)
"Mektovi (Binimetinib) FDA Approval History." Drugs.com, Drugs.com, 2018, (https://www.drugs.com/history/mektovi.html)
‌Center. "Oncology Burst." U.S. Food and Drug Administration, 2023, (https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-encorafenib-binimetinib-metastatic-non-small-cell-lung-cancer-braf-v600e-mutation)